- Novo Nordisk will invest €5.6 billion starting in 2023 to expand manufacturing in Kalundborg, Denmark.
- The investment will create 800 new jobs and employ up to 3,000 external workers during construction.
- The new API facility will cover 170,000 m2 and focus on GLP-1 products.
- Construction will be completed between 2025 and 2029.
Investment Overview
Novo Nordisk plans to invest over €5.6 billion (42 billion Danish kroner) starting in 2023 to expand its manufacturing facilities in Kalundborg, Denmark. This investment aims to enhance capacity for the company's current and future product portfolio, particularly in serious chronic diseases.
Expansion Details
The investment will significantly increase capacity across the global value chain, from the manufacturing of active pharmaceutical ingredients (API) to packaging. The new API facility will be a multi-product facility, designed to accommodate both current and future processes, with a strong focus on GLP-1 products.
Construction and Employment
The new API facility will cover 170,000 m2 and will incorporate state-of-the-art technology and environmentally sustainable practices. The construction projects are scheduled to be completed gradually from the end of 2025 through 2029. Upon completion, the expansion is expected to create 800 new jobs, with 700 in the API facility and 100 in the packaging facility. During the construction phase, up to 3,000 external employees will be employed.
Previous Investments
Over the past two years, Novo Nordisk has announced 40 billion Danish kroner in production investments in Denmark, adding approximately 1,100 employees in production roles. Earlier this year, the company also confirmed it is awaiting approvals for a new production site on Funen, Denmark.
